^
Association details:
| Biomarker: | SORT1 positive |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | sudocetaxel zendusortide (TH 1902) (Tubulin polymerization promoter, Microtubule stabilizer, Sortilin inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation For The Treatment Of Sortilin-Expressing Cancers
Published date:
02/04/2021
Excerpt:
Theratechnologies Inc....is pleased to announce that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.
Trial ID:
